Post by Allucent

The quality of your pharmacokinetic (PK) data can directly impact the quality of your regulatory submission, and as PK analyses become more sophisticated, standardized datasets are increasingly critical. But translating complex pharmacokinetic data into CDISC-compliant datasets isn't always straightforward. From selecting the appropriate standards to ensuring alignment between analysts and data managers, there are several factors that can affect submission readiness. In a recent blog, Allucent experts break down how PK and CDISC intersect, outlining how data from SDTM and ADaM datasets come together to support PK analysis and ensure submission-ready datasets. Read the full blog here: https://lnkd.in/eEvg9Sqr #Allucent #BringingNewTherapiesToLight #CDISC #Pharmacokinetics #ClinicalDataStandards #Biostatistics #PKAnalysis